Search

Displaying results 1991 - 2000 of 7535 in total
  1. Drug

    Mannitol

    go.drugbank.com/drugs/DB00742
    ApprovedInvestigational

    On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for … this indication under the name BRONCHITOL® by Chiesi USA Inc.

  2. Drug

    Rivastigmine

    go.drugbank.com/drugs/DB00989
    ApprovedInvestigational

    Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type.

  3. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms. … [L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks, relieve symptoms in congenital myasthenic syndromes, and protect against certain nerve

    International brands: Kalymin N
  4. Drug

    Sulconazole

    go.drugbank.com/drugs/DB06820
    Approved

    [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial fungal infections.[A255612]

  5. Drug

    Thiotepa

    go.drugbank.com/drugs/DB04572
    ApprovedInvestigational

    It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. … N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years.

    Synonyms: N,N′,N′′-tri-1,2-ethanediyl-, Phosphorothioic triamide, N,N′,N′′-tri-1,2-ethanediyl-
  6. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]

  7. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and [tetracycline].[A19429,L13880]

    Synonyms: N-Lysinomethyltetracycline, N2-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline
  8. Drug

    Ulipristal

    go.drugbank.com/drugs/DB08867
    ApprovedInvestigational

    The exact mechanism of action for ulipristal is still currently debated, though there is evidence that it functions by inhibiting ovulation. … debated due to ethical concerns related to abortion (Rosato et al, 2016).

  9. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that … [L2933] The treatment effect was maintained for up to 12 months.[L2933]

  10. Drug

    Finafloxacin

    go.drugbank.com/drugs/DB09047
    ApprovedWithdrawn

    Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.